EMMAC is a European medical cannabis company that combines scientific research with cultivation, extraction and production to supply medical cannabis, hemp and derivative products. It has supply and distribution partnerships throughout Europe and seeks to be a thought leader and the European leader in the sector. The company plans to use recent proceeds to complete strategic acquisitions and to fund research collaborations aimed at shaping the future of medical cannabis therapeutics. Financially, EMMAC raised £11 million in a private placing that produced a post-money valuation of £77 million; the placing was oversubscribed. The company previously raised £6 million in January 2019, bringing total funds raised in 2019 to £17 million. Management says the funding positions EMMAC to complete the next stage of corporate development and to meet growing market demand driven by regulatory change and increased demand for premium medical cannabis products.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2019